Abstract 5805
Background
Due to their intrinsic thermal and magnetic resonance imaging properties, magnetic nanoparticles (MNCs) have attracted more and more attention in the biomedical field. However, relatively weak photothermal conversion (PTC) efficiency and low tumor homing capacity has hampered its further application in vivo.
Methods
To solve these problems, we modified near-infrared (NIR) light-absorbing materials onto the surface of MNCs to increase PTC efficiency and increase MNCs tumor homing capacity by coated red blood cell (RBC) membranes.
Results
Our data show that after being loaded with NIR cypate molecules, the as-prepared Cyp-MNCs showed remarkably increased NIR absorbance and resultant PTC efficiency compared with the MNCs. By disguising itself, Cyp-MNCs coated with erythrocyte membranes inherit the long circulation characteristics of RBCs to improve the MNCs’ tumor homing capacity. By tracking the NIR fluorescence of cypate under an in vivo fluorescence imaging system, we discovered that such Cyp-MNC@RBCs upon intravenous injection show significantly improved tumor homing capacity compared with bare cypate-loaded MNCs. The antitumor efficiency of biomimetic Cyp-MNC@RBCs was particularly prominent and was superior to biomimetic MNC@RBCs. Additionally, fluorescence and T2-weighted magnetic resonance imaging (MRI) functionalities were all retained attributable to Cyp-MNC@RBCs cores.
Conclusions
Our study would provide a promising procedure for other similarly enhanced photothermal treatments by increasing PTC efficincies and improving tumor-homing capacity.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
920 - Efficacy of intravenous (IV) NEPA, a fixed NK1/5-HT3 receptor antagonist (RA) combination, for prevention of CINV following cisplatin- and anthracycline cyclophosphamide (AC)-based chemotherapy (CT)
Presenter: Lee Schwartzberg
Session: Poster Display session 1
Resources:
Abstract
5146 - Efficacy of olanzapine combination in prevention of nausea & vomiting in highly emetogenic chemotherapy
Presenter: Smitha Saldanha
Session: Poster Display session 1
Resources:
Abstract
1947 - Patient-reported outcome data during real-world use of NEPA for prevention of chemotherapy-induced nausea and vomiting in high-risk platin-receiving patients - A prospective multicenter trial
Presenter: Meinolf Karthaus
Session: Poster Display session 1
Resources:
Abstract
6163 - A study evaluating steroid induced metabolic syndrome after antiemetic dexamethasone therapy in patients received high emetic risk chemotherapy
Presenter: Hee Jun Kim
Session: Poster Display session 1
Resources:
Abstract
2154 - High incidence of nausea during initial and repeated courses if intravenous chemotherapy in patients receiving guideline consistent antiemetic prophylaxis - a prospective, observational, real world study.
Presenter: Teresa Smit
Session: Poster Display session 1
Resources:
Abstract
1637 - "Randomised controlled trial of Scalp Cooling (SC) for the prevention of Chemotherapy Induced Alopecia (CIA)”
Presenter: Jyoti Bajpai
Session: Poster Display session 1
Resources:
Abstract
5351 - Performance of the ‘4S rule’ to predict short-term outcomes in cancer outpatients with unsuspected pulmonary embolism.
Presenter: David Pesántez Coronel
Session: Poster Display session 1
Resources:
Abstract
1189 - Prevalence of venous thromboembolism based on intensive screening for patients with advanced solid tumor in prospective observational study
Presenter: Shota Omori
Session: Poster Display session 1
Resources:
Abstract
4340 - Short-term outcomes of cancer patients with pulmonary embolism according to the setting (hospital-acquired vs. outpatient) at diagnosis.
Presenter: Diego Muñoz Guglielmetti
Session: Poster Display session 1
Resources:
Abstract
4658 - Patient-reported outcomes associated with switching to rivaroxaban for the treatment of venous thromboembolism (VTE) in patients with active cancer
Presenter: Alexander Cohen
Session: Poster Display session 1
Resources:
Abstract